The efficacy of triple H therapy (hypertension, hypervolemia, hemodilution) in SAH cases, which develop vasospasm and vasospasm-related stroke following aneurysm hemorrhage, may in part be explained by HSA-mediated neuroprotection. This evidence concerns the gene ALB and hypertensive disorder.